485 patents
Page 6 of 25
Utility
Venetoclax Dosing Regimens for Use In Treating Myelodysplastic Syndromes In Combination with Azacitidine
1 Dec 22
The invention described herein relates to therapeutic dosing regimens comprising administering venetoclax in combination with azacitidine for treating myelodysplastic syndromes (MDS).
John HAYSLIP, Steve H. KYE, William B. AINSWORTH
Filed: 10 May 22
Utility
Devices and Methods for Delivering a Beneficial Agent to a User
1 Dec 22
A device for delivering a beneficial agent is provided and generally includes a cassette, a pump, and a delivery tube.
Phil Anderson, Kevin Novak, Kevin McLennan, Michael Mackaplow, Guiyong Song, Gurjinder Singh Dhami, Benjamin Alan Jasperson, Scott Smieja, Matthew Svacina
Filed: 20 May 22
Utility
Anti-c-met Antibody Drug Conjugates
1 Dec 22
The present disclosure provides c-Met antibody drug conjugates (ADCs), including compositions and methods of using such ADCs.
Andrew C. PHILLIPS, Regina M. REILLY, George A. DOHERTY, Cheng JI, Milan BRUNCKO, Erwin R. BOGHAERT, Mark ANDERSON
Filed: 29 Apr 22
Utility
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
29 Nov 22
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process.
Ayman Allian, Jayanthy Jayanth, Mohamed-Eslam F. Mohamed, Mathew Mulhern, Fredrik Lars Nordstrom, Ahmed A. Othman, Michael J. Rozema, Lakshmi Bhagavatula, Patrick J. Marroum, Peter T. Mayer, Ahmad Y. Sheikh, Thomas B. Borchardt, Ben Klünder
Filed: 2 May 22
Utility
Combination Therapy of a Type II ANTI-CD20 Antibody with a Selective BCL-2 Inhibitor
24 Nov 22
The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
Filed: 7 Jun 22
Utility
Venetoclax Dosing Regimens for Use In Treating Myelodysplastic Syndromes In Combination with a CYP3A Inhibitor and Azacitidine
24 Nov 22
The invention described herein relates to therapeutic dosing regimens comprising administering venetoclax in combination with azacitidine and a CYP3A inhibitor for treating myelodysplastic syndromes (MDS).
John HAYSLIP, Steve H. KYE, Ahmed SALEM, Jiuhong ZHA
Filed: 10 May 22
Utility
Modulators of the Integrated Stress Pathway
17 Nov 22
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
Carmela Sidrauski, Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei Zhang, Yunsong Tong, Charles W. Hutchins, SeungWon Chung, Michael J. Dart
Filed: 24 Nov 20
Utility
Glucocorticoid Receptor Agonist and Immunoconjugates Thereof
10 Nov 22
Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.
Michael J. McPherson, Adrian D. Hobson, Martin E. Hayes, Christopher C. Marvin, Diana Schmidt, Wendy Waegell, Christian Goess, Jason Z. Oh, Axel Hernandez, Jr., John T. Randolph
Filed: 12 May 21
Utility
Methods for treating HCV
1 Nov 22
The present invention features interferon-free therapies for the treatment of HCV.
Walid M. Awni, Barry M. Bernstein, Andrew L. Campbell, Sandeep Dutta, Chih-Wei Lin, Wei Liu, Rajeev M. Menon, Sven Mensing, Thomas J. Podsadecki, Tianli Wang
Filed: 14 Feb 17
Utility
Isolation and Purification of ANTI-IL-13 Antibodies Using Protein a Affinity Chromatography
27 Oct 22
Disclosed herein are methods for the isolation and purification of anti-IL-13 antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses.
Robert K. Hickman
Filed: 17 May 22
Utility
Purified Antibody Composition
27 Oct 22
The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.
Min M. Wan, George Avgerinos, Gregory Zarbis-Papastoitsis
Filed: 15 Dec 21
Utility
Inhibitors of the menin-MLL interaction
25 Oct 22
The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Andrew Marcus, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun Zheng, Linghang Zhuang, Stephan D. Parent, Travis L. Houston
Filed: 1 Apr 20
Utility
Pharmaceutical Formulations of a Bruton's Tyrosine Kinase Inhibitor
20 Oct 22
Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.
Ching W. Chong, Robert Kuehl, Heow Tan, Harisha Atluri
Filed: 29 Nov 21
Utility
Multispecific Heavy Chain Antibodies with Modified Heavy Chain Constant Regions
20 Oct 22
Multispecific, human heavy chain antibodies (e.g., UniAbs™) that have modified heavy chain constant regions that impart advantageous properties are provided.
Katherine Harris, Ute Schellenberger, Omid Vafa, Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Duy Pham, Starlynn Clarke
Filed: 23 Nov 21
Utility
Systems and Methods for Identifying Protein Aggregates In Biotherapeutics
13 Oct 22
Systems and methods for inspecting particles in a liquid beneficial agent are provided.
Edmund Matayoshi, Shen Tu, Jie Wang
Filed: 25 Jan 22
Utility
Methods of Treatment of Non-small-cell Lung Carcinoma Using Telisotuzumab Vedotin
13 Oct 22
The present disclosure provides improved methods of treatment of NSCLC cancers using telisotuzumab vedotin.
Janet Yikai JIN, Philip B. KOMARNITSKY, Mirella LAZAROV, Anita REDDY
Filed: 6 Apr 22
Utility
Elagolix Sodium Compositions and Processes
13 Oct 22
The present invention relates to compositions of elagolix sodium, and process and intermediates for the preparation thereof.
Niharika Chauhan, Raimundo Ho, Albert Kruger, Samrat Mukherjee, Stephen T. Chau, Erika Crane, Alex Fabian, Sanjay Chemburkar, Travis Dunn
Filed: 14 Apr 22
Utility
Apoptosis Inducing Agents for the Treatment of Cancer and Immune and Autoimmune Diseases
6 Oct 22
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
Milan BRUNCKO, Hong DING, George A. DOHERTY, Steven W. ELMORE, Lisa A. HASVOLD, Laura HEXAMER, Aaron R. KUNZER, Xiaohong SONG, Andrew J. SOUERS, Gerard M. SULLIVAN, Zhi-Fu TAO, Gary T. WANG, Le WANG, Xilu WANG, Michael D. WENDT, Robert MANTEI, Todd M. HANSEN
Filed: 3 Nov 21
Utility
Automatic Injection Device
6 Oct 22
Automatic injection device includes a housing, a syringe, a plunger, and a syringe carrier.
Sherwin S. Shang, Eduard N. Tsvirko, Edwin Chim, Shubha Chethan Somashekar, Esra Ozdaryal, Joseph F. Julian, Chuan Li
Filed: 19 Nov 21
Utility
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
29 Sep 22
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3Himidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
Aileen L. Pangan, Henrique D. Teixeira, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Ben Klünder
Filed: 27 May 22